Health and Fitness Health and Fitness
Tue, December 13, 2011
[ Tue, Dec 13th 2011 ] - Market Wire
Die Europische Kommission erteilt Astellas Pharma .. zulassung zur Verwendung von DIFICLIRa" in der EU
[ Tue, Dec 13th 2011 ] - Market Wire
La Comisin Europea concede la autorizacin de mark .. Astellas Pharma Europe Ltd., para su uso en la UE
[ Tue, Dec 13th 2011 ] - Market Wire
PhotoMedex and Radiancy Complete Merger
[ Tue, Dec 13th 2011 ] - Market Wire
Bio-Path Holdingsa Initial Phase I Data in Leukem .. s That Its Neutral Lipid Delivery Technology Anti
[ Tue, Dec 13th 2011 ] - Market Wire
Thera Maxa" Cold and Flu Debuts in Times Square D .. ring the Height of the 2011 / 2012 Holiday Season
[ Tue, Dec 13th 2011 ] - Market Wire
Direction of Market Influences - Report Highlight .. uestcor Pharmaceuticals, Inc. and Perrigo Company
[ Tue, Dec 13th 2011 ] - Market Wire
Direction of Market Influences - Report Highlight .. ceutical Industries Ltd (ADR) and Sanofi SA (ADR)
[ Tue, Dec 13th 2011 ] - Market Wire
A Change in Tides - Featured Research on Tenet Healthcare Corporation and Deluxe Corporation
[ Tue, Dec 13th 2011 ] - Market Wire
A Potent and Safe Wound Care Agent
[ Tue, Dec 13th 2011 ] - Market Wire
GenVec President and Chief Executive Officer Announces Retirement
[ Tue, Dec 13th 2011 ] - Market Wire
Keryx Biopharmaceuticals Announces Phase 2 Data f .. e) in Hodgkin's Lymphoma Presented at ASH Meeting
[ Tue, Dec 13th 2011 ] - Market Wire
New Clinical Study Presented at the NYPGA Meeting .. oring -- Considered the Fourth Primary Vital Sign
[ Tue, Dec 13th 2011 ] - Market Wire
China Botanic Announces Development of New Siberian Ginseng Polysaccharide Extract Powder
[ Tue, Dec 13th 2011 ] - Market Wire
Encouraging Clinical Data for Perifosine in Hodgkin Lymphoma Presented at ASH Meeting
[ Tue, Dec 13th 2011 ] - Market Wire
Baxter Signs Definitive Agreement to Acquire Synovis
[ Tue, Dec 13th 2011 ] - Market Wire
St. Jude Medical Board of Directors Authorizes Share Repurchase and Fourth Quarter Dividend
[ Tue, Dec 13th 2011 ] - Market Wire
SANUWAVE Technology Shown to Proliferate Adult Stem Cells
[ Tue, Dec 13th 2011 ] - Market Wire
Cubist Announces First Patient Dosed in Pivotal G .. XA-201 for Complicated Intra-Abdominal Infections
[ Tue, Dec 13th 2011 ] - Market Wire
Alnylam Scientists Present New Data on RNAi Therapeutics at 53rd ASH Annual Meeting
[ Tue, Dec 13th 2011 ] - Market Wire
Estudio de Fase II evala la ventaja clnica de pom .. con mieloma mltiple con pretratamiento intensivo
[ Tue, Dec 13th 2011 ] - Market Wire
Fase 2-onderzoek evalueert klinisch profijt van p .. j eerder behandelde patinten met multipel myeloom
[ Tue, Dec 13th 2011 ] - Market Wire
Endgltige Daten aus multizentrischer Phase-II-Stu .. binationstherapie von VIDAZA und REVLIMID fr MDS-
[ Tue, Dec 13th 2011 ] - Market Wire
Presentados en ASH los datos finales de un estudi .. evala la combinacin de VIDAZA y REVLIMID en pacie
[ Tue, Dec 13th 2011 ] - Market Wire
Phase-II-Studie von ISTODAX bei Patienten mit rez .. peripheres T-Zell-Lymphom): Prsentation der Teila
[ Tue, Dec 13th 2011 ] - Market Wire
Estudio de Fase II de ISTODAX en pacientes con li .. (PTCL) recurrente o resistente: presentado en ASH
[ Tue, Dec 13th 2011 ] - Market Wire
Fase II onderzoek van ISTODAX bij patinten met re .. len perifeer t-cel lymfoom (PTCL): subanalyse van
[ Tue, Dec 13th 2011 ] - Market Wire
Nektar Announces Positive Clinical Data from Seco .. NKTR-181, a Novel Opioid Analgesic Molecule to Tr
[ Tue, Dec 13th 2011 ] - Market Wire
Aethlon Medical Announces HIV-AIDS Research Discovery
[ Tue, Dec 13th 2011 ] - Market Wire
Stem Cell Therapeutics Announces Additions to Advisory Board
[ Tue, Dec 13th 2011 ] - Market Wire
Eindgegevens van Fase II multi-center onderzoek n .. REVLIMID bij patinten met hoogrisico MDS gepresen

Eindgegevens van Fase II multi-center onderzoek naar combinatie van VIDAZA en REVLIMID bij patinten met hoogrisico MDS gepresen


Published on 2011-12-13 03:27:33 - Market Wire
  Print publication without navigation


BOUDRY, Switzerland--([ ])--Celgene International Srl, een dochteronderneming van Celgene Corporation (NASDAQ: CELG), meldt de eindresultaten van het Fase II onderdeel van een multi-center Fase I/II onderzoek dat de combinatietherapie evalueerde van REVLIMID (lenalidomide) en VIDAZA (azacitidine) bij patinten met hoogrisico myelodysplastische syndromen (MDS), die niet eerder behandeld werden met een van de twee middelen. De gegevens werden gepresenteerd op de 53ste jaarvergadering van de Amerikaanse Vereniging voor Hematologie in San Diego. Bij patinten met een volledige respons trad een gemiddelde overleving op van 27 maanden.

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal welke als enige juridische geldigheid beoogt.

Contributing Sources